EMA Authorised: Pheburane (sodium phenylbutyrate) — Eurocept International B. V.

View source ↗

Summary

EMA authorised Pheburane (sodium phenylbutyrate) for Carbamoyl-Phosphate Synthase I Deficiency disease, under Eurocept International B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carbamoyl-phosphate Synthase Deficiency Disease

Drugs mentioned

• Pheburane (sodium phenylbutyrate)

Snippet

Status: Authorised. Therapeutic area: Carbamoyl-Phosphate Synthase I Deficiency Disease. MAH: Eurocept International B. V.. Decision date: 29/05/2026